ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display…
ImmunoPrecise Antibodies (IPA) Stock Price, News & Analysis
Date:
More like thisRelated
Tampa RV giant Lazydays to delist from Nasdaq
Tampa-based Lazydays Holdings Inc., one of Florida’s most recognized...
Granite Geek: New Hampshire might get access to ‘balcony solar’
I had solar panels put on my roof six...
TSX Today: What to Watch for in Stocks on Monday, November 10
Despite firm gold and silver prices, Canadian stocks...
While BNB and DOT Struggle Under Market Pressure, BlockDAG’s Presale Soars Past $435M!
As market-wide fear grips the sector, the Binance Coin...